On January 29, 2025, the U.S. Court of Appeals for the Federal Circuit affirmed the District Court for the Northern District of West ...

(RTTNews) - EyePoint Pharmaceuticals, Inc. (EYPT), Wednesday announced positive six-month results from the ongoing Phase 2 VERONA clinical trial, evaluating Duravyu for the treatment of diabetic ...

The two products, both manufactured by Amgen, are aflibercept biosimilars Pavblu and Skojoy. Both biosimilars are indicated ...

Lower rates of both progression of macular fibrosis and intravitreal aflibercept injections were found in those who used the ...

Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ:EYPT) tumbled 21% following the release of positive clinical trial results for their DURAVYU™ treatment, confounding analysts who viewed the ...

CHMP Adopts Positive Opinion for Aflibercept, Pegfilgrastim Biosimilars:  On January 30, 2025, the European Medicines Agency (EMA) Committee ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended 3 biosimilars and new indications for reference biologics, moving them closer to final European ...

Pharmaceuticals announced positive six-month results for the ongoing Phase 2 VERONA clinical trial evaluating DURAVYU, an ...

Formycon's biosimilar candidate to Eylea ® (aflibercept) in Europe, excluding Italy, and in Israel. This collaboration combines Teva’s deep commercial experience in biosimilars and its ...